In a second in vivo model, the tumor cells expressed low levels of FR-α, and high levels of EGFR, the combination of the Onc.Ad with CAR-T cells resulted in sustained reduction of tumor volume compared to single agent treatments. Here, FOLR1 is linked to neoplasm.